{"id":13384,"date":"2023-09-27T23:12:00","date_gmt":"2023-09-27T15:12:00","guid":{"rendered":"https:\/\/flcube.com\/?p=13384"},"modified":"2024-11-18T23:22:07","modified_gmt":"2024-11-18T15:22:07","slug":"suzhou-novoprotein-and-shanghai-model-organisms-center-ink-global-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13384","title":{"rendered":"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership"},"content":{"rendered":"\n<p>Suzhou Novoprotein Scientific Co., Ltd, (<a href=\"https:\/\/www.google.com\/finance\/quote\/688137:SHA\">SHA: 688137<\/a>) a leading provider of protein technology and application solutions in China, has entered into a strategic partnership with Shanghai Model Organisms Center, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688265:SHA\">SHA: 688265<\/a>). The collaboration aims to combine the companies&#8217; expertise on a global scale, focusing on technology and commerce. Novoprotein brings its strengths in antibody drugs, mRNA vaccine drugs, cell and gene therapy (CGT), organoids, and genetically modified animal models to the partnership, while leveraging Shanghai Model Organisms&#8217; complementary capabilities.<\/p>\n\n\n\n<p><strong>Scope of Collaboration<\/strong><br>The partnership will see the two companies working closely together to advance their respective fields. Novoprotein&#8217;s expertise in antibody drugs and mRNA vaccine drugs positions the company at the forefront of biotechnology innovation. The company&#8217;s capabilities in CGT and organoids, along with its strengths in genetically modified animal models, will be instrumental in driving the partnership&#8217;s objectives. Shanghai Model Organisms, with its own edge in the industry, will contribute to the collaboration, enhancing the potential for groundbreaking developments in the life sciences sector.<\/p>\n\n\n\n<p><strong>Financial Details and Future Outlook<\/strong><br>While no financial details of the partnership have been disclosed, the alliance signals a significant commitment by both parties to explore new opportunities in the global market. The partnership is expected to yield synergies that will benefit both companies and contribute to the advancement of protein technology and application solutions on a global scale.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,66,2166,63,2165,2167,2164],"class_list":["post-13384","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cell-therapy","tag-gene-therapy","tag-model-organisms-center","tag-mrna","tag-novoprotein-scientific","tag-sha-688137","tag-sha-688265"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Novoprotein Scientific Co., Ltd, a leading provider of protein technology and application solutions in China, has entered into a strategic partnership with Shanghai Model Organisms Center, Inc. (SHA: 688265). The collaboration aims to combine the companies&#039; expertise on a global scale, focusing on technology and commerce. Novoprotein brings its strengths in antibody drugs, mRNA vaccine drugs, cell and gene therapy (CGT), organoids, and genetically modified animal models to the partnership, while leveraging Shanghai Model Organisms&#039; complementary capabilities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13384\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13384\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-27T15:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-18T15:22:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13384#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13384\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership\",\"datePublished\":\"2023-09-27T15:12:00+00:00\",\"dateModified\":\"2024-11-18T15:22:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13384\"},\"wordCount\":240,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\",\"Gene therapy\",\"Model Organisms Center\",\"mRNA\",\"Novoprotein Scientific\",\"SHA: 688137\",\"SHA: 688265\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13384#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13384\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13384\",\"name\":\"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-09-27T15:12:00+00:00\",\"dateModified\":\"2024-11-18T15:22:07+00:00\",\"description\":\"Suzhou Novoprotein Scientific Co., Ltd, a leading provider of protein technology and application solutions in China, has entered into a strategic partnership with Shanghai Model Organisms Center, Inc. (SHA: 688265). The collaboration aims to combine the companies' expertise on a global scale, focusing on technology and commerce. Novoprotein brings its strengths in antibody drugs, mRNA vaccine drugs, cell and gene therapy (CGT), organoids, and genetically modified animal models to the partnership, while leveraging Shanghai Model Organisms' complementary capabilities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13384#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13384\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13384#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Novoprotein Scientific Co., Ltd, a leading provider of protein technology and application solutions in China, has entered into a strategic partnership with Shanghai Model Organisms Center, Inc. (SHA: 688265). The collaboration aims to combine the companies' expertise on a global scale, focusing on technology and commerce. Novoprotein brings its strengths in antibody drugs, mRNA vaccine drugs, cell and gene therapy (CGT), organoids, and genetically modified animal models to the partnership, while leveraging Shanghai Model Organisms' complementary capabilities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13384","og_locale":"en_US","og_type":"article","og_title":"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13384","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-09-27T15:12:00+00:00","article_modified_time":"2024-11-18T15:22:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13384#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13384"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership","datePublished":"2023-09-27T15:12:00+00:00","dateModified":"2024-11-18T15:22:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13384"},"wordCount":240,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy","Gene therapy","Model Organisms Center","mRNA","Novoprotein Scientific","SHA: 688137","SHA: 688265"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13384#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13384","url":"https:\/\/flcube.com\/?p=13384","name":"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-09-27T15:12:00+00:00","dateModified":"2024-11-18T15:22:07+00:00","description":"Suzhou Novoprotein Scientific Co., Ltd, a leading provider of protein technology and application solutions in China, has entered into a strategic partnership with Shanghai Model Organisms Center, Inc. (SHA: 688265). The collaboration aims to combine the companies' expertise on a global scale, focusing on technology and commerce. Novoprotein brings its strengths in antibody drugs, mRNA vaccine drugs, cell and gene therapy (CGT), organoids, and genetically modified animal models to the partnership, while leveraging Shanghai Model Organisms' complementary capabilities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13384#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13384"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13384#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13384"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13384\/revisions"}],"predecessor-version":[{"id":13387,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13384\/revisions\/13387"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}